Akums Drugs and Pharma IPO listing: Shares list at 6.7% premium to issue price on NSE & BSE

2 min read | Updated on August 06, 2024, 10:52 IST

SUMMARY

Akums Drugs and Pharma IPO consists of a fresh issue of shares valued at ₹680 crore and an offer-for-sale (OFS) component of 1.73 crore shares aggregating to ₹1,177 crore by promoters Sandeep and Sanjeev Jail and an investor Ruby QC Investment Holdings Pte Ltd.

Akums Drugs and Pharmaceuticals had raised ₹829 crore in the anchor round.

Shares of Akums Drugs and Pharmaceuticals made a decent Dalal Street debut on Tuesday, August 6. The stock opened at a premium of 6.7% at ₹725 per share as against the issue price of ₹679 on the National Stock Exchange

The issue received an overall subscription of 63.56 times led by qualified institutional buyers (QIBs), who subscribed 90.09 times the portion set aside for them. The IPO was open for bidding from July 30 to August 1.

The quota for non-institutional investors (NIIs) was subscribed 42.21 times, while the retail investors' category received 21.30 times subscription.

The IPO consists of a fresh issue of shares valued at ₹680 crore and an offer-for-sale (OFS) component of 1.73 crore shares aggregating to ₹1,177 crore by promoters Sandeep and Sanjeev Jail and an investor Ruby QC Investment Holdings Pte Ltd.

The fresh funds generated from the IPO will be used for inorganic growth initiatives, debt repayment, working capital requirements, and general corporate purposes.

About Akums Drugs and Pharmaceuticals

Akums is a pharmaceutical CDMO (Contract development and manufacturing organization) that provides a wide range of pharmaceutical products and services in domestic and international markets.

The company's key clients include Sun Pharmaceutical Industries, Dr Reddy's Laboratories, Alembic Pharmaceuticals, Dabur India, Ipca Laboratories, Hetero Healthcare, Mankind Pharma, Amishi Consumer Technologies (The Mom's Co), Micro Labs, Natco Pharma, Cipla, Alkem Laboratories, Mylan Pharmaceuticals, and MedPlus Health Services.

It also has overseas clients, such as Allegens (Vietnam), Caferma SAC (Peru), Ambica International (Philippines), JDS (Myanmar), Olainfarm (Latvia), Master Pharma (Cambodia), Pharma Apex (Myanmar), Unisel (Kenya), and Planet Pharmaceutical (Tanzania).

Akums Drugs: Financials

Particulars	FY22	FY23	FY24
Revenue	₹ 3,671 crore	₹ 3,654 crore	₹ 4,178 crore
Net Profit/Loss	₹ -250.8 crore	₹ 97.8 crore	₹ 0.79 crore

To know more about IPO listings, schedule and upcoming IPOs, click here.

About The Author

Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | CDSL Reg No.: IN-DP-761-2024 | CIN: U65100DL2021PTC376860 | Compliance Officer: Mr. Kapil Jaikalyani. Tel No.: (022) 24229920. Email ID: compliance@upstox.com | Registered Address: 809, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001 | RKSV Commodities India Pvt. Ltd.: SEBI Registration No.: INZ000015837 | MCX TM Code: 46510 | CIN: U74900DL2009PTC189166 | Compliance Officer: Mr. Amit Lalan. Tel No.: (022) 24229920. Email ID: compliance@rksv.in | Registered Address: 807, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001. Correspondence Address: 30th Floor, Sunshine Tower, Senapati Bapat Marg, Dadar (West), Mumbai - 400013. | For any complaints, email at complaints@upstox.com and complaints.mcx@upstox.com.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES include: Name, PAN, Address, Mobile Number, and E-mail ID. Benefits include effective communication and speedy redressal of grievances. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI, along with our Terms of Use and Privacy Policy.

Upstox Securities Private Limited is a wholly owned subsidiary of RKSV Securities India Private Limited and RKSV Commodities India Private Limited is an associate of RKSV Securities India Private Limited.

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing.
*Brokerage will not exceed the SEBI prescribed limit.

Risk disclosures on derivatives -

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Mutual Funds: Top rated funds do not constitute any advice. Research data is powered by Morningstar. Please read the offer documents carefully before investing. Upstox shall not accept any liability arising out of your investments.
These are not Exchange traded products, and the Member is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

Attention Investors: As per NSE circular dated July 6, 2022, BSE circular dated July 6, 2022, MCX circular dated July 11, 2022 investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. Investors are further cautioned to avoid practices like:
a) Sharing i) trading credentials – login id & passwords including OTP’s., ii) trading strategies, iii) position details.
b) Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c) Writing/ selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks
d) Dealing in unsolicited tips through like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e) Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.

Kindly, read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets : Advisory Guidelines For Investors

Kindly, read the advisory as prescribed by the Exchange with reference to their circular dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: KYC Updation

Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from CDSL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Upstox or RKSV and offering such services, please send us an email at complaints@upstox.com and complaints.mcx@upstox.com.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account. Stockbrokers can accept securities as margin from their clients only by way of a pledge in the depository system w.e.f. 1st September 2020.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number to create a pledge.
Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL/CDSL every month.

Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies. https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the-indian-securities-market_74794.html ODR portal for Investors - https://smartodr.in/login

Akums Drugs and Pharma IPO listing: Shares list at 6.7% premium to issue price on NSE & BSE

About Akums Drugs and Pharmaceuticals

Akums Drugs: Financials

Market Wrap, December 20: SENSEX, NIFTY50 nosedive again; both indices tumble around 5% this week

Mamata Machinery IPO subscribed over 34 times on Day 2, retail investors, NIIs lead; check key dates

International Gemmological Institute shares settle 7.4% lower after listing at 22% premium

KPI Green Energy, Sagility India and SPML Infra are among key stocks to hit the circuit today

Trade setup: Bearish weekly close for NIFTY?

Trade setup: Will NIFTY hold THIS crucial support zone?